Combination of apatinib mesylate and second-line chemotherapy for treating gastroesophageal junction adenocarcinoma

Abstract

Objective To investigate the safety and efficacy of acitinib mesylate combined with chemotherapy in the treatment of patients with gastroesophageal junction adenocarcinoma. Methods A total of 119 patients with gastroesophageal junction adenocarcinoma were enrolled and randomized into an experimental group (n = 60) and a control group (n = 59). Both groups were treated with a combination of taxane, irinotecan and fluorouracil, while the experimental group also received acitinib mesylate. The clinical efficacy, survival time and adverse reactions of patients in two groups were recorded and analyzed. Results The total remission rate in the experimental group and the control group was 15.79% and 3.23%, respectively; the disease control rate was 73.68% and 54.84%, respectively; and progression-free survival was 3.72 months (1–13.5 months) and 3.04 months (1–6 months), respectively. Overall survival was 13.66 months (5–24 months) and 10.08 months (6.5–19.5 months), in the experimental group and the control group, respectively. In addition, the incidence of adverse events in the experimental group was significantly lower than that in the control group. Conclusion Apatinib mesylate combined with chemotherapy for the treatment of patients with gastroesophageal junction adenocarcinoma was safe and effective, with improved survival benefit compared with control.

Efficacy and safety of intermittent versus continuous dose apatinib plus docetaxel as second-line therapy in patients with advanced gastric cancer or gastroesophageal junction adenocarcinoma: a randomized controlled study

“…Another prospective cohort study found that the addition of apatinib to chemotherapy promotes DCR and PFS compared with chemotherapy alone, and independently correlates with less disease progression after multivariate adjustment as a second-or later-line therapy in GC/GEJAC (23). Furthermore, a randomized controlled study showed that apatinib plus second-line chemotherapy achieved a better DCR, PFS, and OS, as well as fewer adverse events compared to chemotherapy alone in patients with advanced GEJAC (24). In our study, the numerical ORR, DCR, and PFS in both groups were in line with previous studies, while the OS was numerically longer (median OS of 9.0 months in the IG group and 9.4 months in the CG group) compared with that in previous studies that used chemotherapy alone [median OS of 5.2 months in the COUGAR-02 study (docetaxel), 7.4 months in the RAINBOW study (paclitaxel), and 8.3 months in the Keynote-061 study (paclitaxel)] (11,25,26).…”

Advances in targeted therapy and immunotherapy for esophageal cancer

“…Clinical trials indicated that apatinib alone or combined with chemotherapy was effective and safe for treating advanced EC. [5155] In addition, other clinical trials have confirmed the synergistic effect of low-dose apatinib combined with camrelizumab. [5659] Apatinib may be an option for the treatment of advanced EC.…”

A Phase I Dose Escalation Study of Apatinib Combinated with Docetaxel as Second-line Therapy for Advanced Gastric Carcinoma

“…Combination therapy significantly improved progression-free survival (PFS) and disease control rate (DCR) [12] . Apatinib combined with chemotherapy also demonstrated improved survival benefit in two other studies [13,14] . However, phase 1 dose-escalation studies of apatinib combined with chemotherapy are lacking.…”